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Recent  years  have  brought  in an  increased  interest  to develop  improved  polymyxins.  The  currently  used
polymyxins,  i.e.  polymyxin  B  and  colistin  (polymyxin  E) are  pentacationic  lipopeptides  that  possess  a
cyclic  heptapeptide  part  with  three  positive  charges,  a linear  “panhandle”  part with  two  positive  charges,
and  a  fatty  acyl  tail. Unfortunately,  their  clinical  use  is  shadowed  by  their  notable  nephrotoxicity.  We
have  previously  developed  a polymyxin  derivative  NAB739  which  lacks  the  positive  charges  in  the  linear
part.  This  derivative  is better  tolerated  than  polymyxin  B in cynomolgus  monkeys  and  is,  in contrast  to






relationship  (SAR)  studies  on  17  derivatives  with  three  positive  charges  only.  We  discovered  a  remarkably
antibacterial  class,  as  exemplified  by  NAB815,  that carries  two  positive  charges  only  in  the  cyclic  part.
© 2017  Elsevier  Inc.  All  rights  reserved.K-2
. Introduction
Recent years have brought in an increased interest to develop
mproved polymyxins for the therapy of severe infections caused by
xtremely antibiotic-resistant Gram-negative bacteria, as reviewed
y Pirri et al. [10], Vaara [12], Kadar et al. [5] Cochrane and Vederas
2] and Velkov et al. [19].
The currently used polymyxins, i.e. polymyxin B and colistin
polymyxin E) were discovered as early as 1947. They are penta-
ationic lipopeptides that possess a cyclic heptapeptide part with
hree positive charges, a linear “panhandle” part with two positive
harges, and a fatty acyl tail (methyloctanoyl in polymyxin B1 and
olistin A, or methylheptanoyl in polymyxin B2 and colistin B). For
he structure of polymyxin B, see Fig. 1.Polymyxin B and colistin (administered as its inactive methane-
ulphonate prodrug CMS) are effective against most species of
nterobacteriaceae as well as Acinetobacter baumannii and Pseu-
∗ Corresponding author at: Northern Antibiotics Ltd., Technopolis, Tekniikantie
4, FI-02150 Espoo, Finland.
E-mail address: martti.vaara@northernantibiotics.com (M. Vaara).
ttp://dx.doi.org/10.1016/j.peptides.2017.03.002
196-9781/© 2017 Elsevier Inc. All rights reserved.domonas aeruginosa but both were largely abandoned in the
sixties because of nephrotoxicity and increased availability of
more effective antibiotics [4–6,12]. According to recent studies, the
nephrotoxicity rate of polymyxin B and colistin varies from 20% to
60%. Furthermore, pharmacokinetic data indicates that the current
dosage regimens are suboptimal [3]. Therefore, larger doses should
be used, but this further increases the risk of nephrotoxicity.
We have previously developed polymyxin derivatives such as
NAB739 (Table 1) which lack the positive charges in the linear part
and accordingly carry three positive charges only [12–15]. In con-
trast to the old polymyxins that are effectively reabsorbed by the
proximal tubular kidney cells and not excreted as a biologically
active form into urine, NAB739 and compounds related to it yield
very high concentrations in the urine [12,14,17]. This is remarkable,
since most of the bacteremic infections caused by Enterobacteri-
aceae originate from complicated urinary tract infections. NAB739
has reduced affinity for the brush border membrane of the proxi-
mal  tubular cells and was shown to be less toxic than polymyxin B
to these cells by a factor of more than 20 [13,16]. Preclinical studies















Structure of the compounds, their activity against E. coli, and their toxicity to HK-2 cells.a
IC50   (µg/ml)c) for
Compoun d R (FA) R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 E.  coli  AT2 592 2 E. c oli  I H308 0  HK-2 cells
Polymyxin  B MOA /MHA  -Dab+  -Th r  -Dab+  -cy[Dab  -Dab+  -DPhe  -Le u  -Dab+  -Dab+  -Th r] 0,5 (0,5-1) [15 ] 0,5 (0,5-1) [15 ] 18 ,0 (7,6 - 38 ) [4]
NAB73 9 OA  -  -Th r  -DSer  -cy[Dab  -Dab+  -DPhe  -Le u  -Dab+  -Dab+  -Th r] 2 (1-4) [30 ] 2 (1-4) [30 ] 237  (184 -275 ) [3]
NAB807 OA  -  -Thr  -DTh r  -cy[Dab  -Dab+  -DPhe  -Leu  -Dab+  -Dab+  -Thr] 4 (2-4) [6] 4 (4-8) [6] 235
NAB809 OA  -  -Thr  -DHSer  -cy[Dab  -Dab+  -DPhe  -Leu  -Dab+  -Dab+  -Thr] 16 [3] 16 (16-32) [3]  -
NAB743 OA  -  -Thr  -Ser  -cy[Dab  -Dab+  -DPhe  -Leu  -Dab+  -Dab+  -Thr] ≥ 32 [3] 16 [3] 113
NAB80 5 OA  -  -Th r Th r  -cy[Dab  -Dab+  -DPhe  -Le u  -Dab+  -Dab+  -Th r] ≥ 32 [3] ≥ 32 [3] 221
NAB80 3 OA  -  -Th r HSer  -cy[Dab  -Dab+  -DPhe  -Le u  -Dab+  -Dab+  -Th r] ≥ 32 [3] ≥ 32 [3] 317
NAB81 3 OA  -Dab+  -Th r  -DSer  -cy[Dab  -Dab+  -DPhe  -Le u  -Abu  -Dab+  -Th r] 2 [6] 2 [6]  -
NAB81 9 NA  -Dab+  -Th r  -DSer  -cy[Dab  -Dab+  -DPhe  -Le u  -Abu  -Dab+  -Th r] 2 [3] 2 [3]  -
NAB81 2 OA  -Dab+  -Th r  -DSer  -cy[Dab  -Dab+  -DPhe  -Le u  -Ser  -Dab+  -Th r] 2 [3] 2 (1-2( [3]  -
NAB81 8 OA  -Dab+  -Th r  -DSer  -cy[Dab  -Dab+  -DPhe  -Le u  -Ser  -Dab+  -Th r] 2 [3] 2 (1-2( [3]  -
NAB815 OA  -Dab+  -Thr  -DThr  -cy[Dab  -Dab+  -DPhe  -Leu   -Abu  -Dab+  -Thr] 2 (2-4)  [24] 2 (2-4) [24] 334
NAB820 NA  -Dab+  -Thr  -DTh r  -cy[Dab  -Dab+  -DPhe  -Leu   -Abu  -Dab+  -Thr] 4 (2-4) [3] 2 [3]  -
NAB81 4 OA  -Dab+  -Th r  -DTh r  -cy[Dab  -Dab+  -DPhe  -Le u  -Ser  -Dab+  -Th r] 2 [3] 2 [3]  -
NAB82 1 OA  -Dab+  -Th r  -DTh r  -cy[Dab  -Dab+  -DPhe  -Le u    -Le u  -Dab+  -Th r] 4 (4-8) [3] 4 (4-8) [3]  -
NAB816 OA  -  -Dab+  -DTh r  -cy[Dab  -Dab+  -DPhe  -Leu  -Abu  -Dab+  -Thr] > 64 [3] > 64 [3]  -
NAB817 OA  -  -Thr   -Dap+  -cy[Dab  -Dab+  -DPhe  -Leu   -Abu  -Dab+  -Thr] 16 [3] 8 [3]  -
NAB82 2 OA  -Dab+  -Th r  -DTh r  -cy[Dab  -Dab+  -DPhe  -Le u    -Abu  -Dab+  -Leu ] 64  (64  - >64) [3] 8 [3]  -
NAB823 OA  -Dab+  -Thr  -DTh r  -cy[Dab  -Dab+  -DPhe  -Leu   -Leu  -Dab+  -Leu] 16 (16-32) [3] 8 [3]  -
NAB82 4 OA  -  -Th r  -DSer  -cy[Dab  -Dab+  -DPhe  -Le u  -Dab+  -Dab+  -Leu ] 32  (16 -32 ) [3] 16 [ 3] 56
MIC (µg/ml)b) f or 
aAbbreviations: MOA/MHA, a mixture of methyloctanoic and methylheptanoic acid; OA, octanoic acid; NA, nonanoic acid; Abu, aminobutyric acid; Dab, diaminobutyric acid; Fser, homoserine; cy indicates the R4-R10 ring.
bMedian, range (in parentheses), number of determinations (in brackets). Median values <4 in bold.
cGeometric mean, range (in parentheses), number of determinations (in brackets). Values >100 in bold.








































ig. 1. The structure of polymyxin B1. The fatty acyl “tail” is highlighted in pink and 
2  carries 6-methyl heptanoic residue as the fatty acyl tail.
NAB739 lacks the residue R1 (diaminobutyric acid, Dab) and
arries DSer at the position R3 instead of Dab (residue number-
ng according to that of polymyxin B and colistin with residues
1–R10). In structure–activity relationship (SAR) studies, R3 is one
f the last “uncharted” positions. We  postulated that in derivatives
ith three positive charges only, a hydrophilic residue carrying
 hydroxyl group at R3 is advantageous for antibacterial activity,
ince a derivative identical to NAB739 but carrying aminobutyric
cid (Abu) at R3 lacks direct antibacterial activity. In this commu-
ication, we have compared the activity of NAB739 with our newer
erivatives that carry certain other residues than D-Ser at R3. Fur-
hermore, our previous studies have given indirect evidence that in
he ring part the positive charge at R8 due to a Dab residue is less
mportant for the antibacterial activity than the Dab residues at R5
nd R9. Here we show that it is indeed possible to design directly
ntibacterial derivatives with three positive charges only but no
ore than two of them in the ring part.
. Materials and methods
.1. Peptides
Milligram-scale synth of polymyxin derivatives was  performed
y conventional solid-phase chemistry at Alta Bioscience, Birm-
ngham, United Kingdom, as described previously [13]. Briefly,
he -amino group was protected by fluorenylmethoxycarbonyl
Fmoc), the -amino group of the Dab residue involved in cycliza-
ion of the peptide by t-butoxycarbonyl (tBoc), and all the other
unctional side chain groups by benzyloxycarbonyl (Z). Acyla-
ion was performed for 30 min  by using a 4-fold molar excess
f each amino acid or the fatty acid. The cyclization mixture
as added to the peptide (dissolved in dimethylformamide) and
llowed to react for 2 h. The cyclized, protected peptide was
recipitated by the addition of cold diethyl ether and washed
ith water. The remaining side chain protection groups (Z) were
emoved by catalytic hydrogenation as described previously [13].
he peptides were purified by HPLC using conventional gradients
f acetonitrile–water–trifluoroacetic acid and the eluate fractions
orresponding to the peptides were lyophilized. The peptide purity,
stimated by HPLC, was more than 95%. All peptides were studied
n their trifluoroacetate salt form.
Gram-scale synthesis of NAB739 sulfate and NAB815 sulfate was
erformed by Bachem AG (Bubendorf, Switzerland). The purity, asear peptide part in yellow. The five free amino groups are marked in red. Polymyxin
estimated by HPLC, was 97.3% for NAB739 and 98.4% for NAB815.
Polymyxin B sulfate was from Sigma–Aldrich (St. Louis, MO,  USA;
product number PO972).
2.2. Bacterial strains
Seven ATCC strains were used: Escherichia coli ATCC25922,
Klebsiella pneumoniae ATCC13883, A. baumannii ATCC19606, P.
aeruginosa ATCC27853, Staphylococcus aureus ATCC25923, S. aureus
ATCC29123, and Enterococcus faecalis ATCC29112. E. coli IH3080
(K1:O18:H7) is a virulent encapsulated strain [13,18], and E. coli
SC 9253 is a well-characterized polymyxin-resistant pmrA mutant
of E. coli K-12 [8,9,13]. Both strains have widely been used in our
previous studies. The tolC construct of E. coli ATCC25922, the E. coli
K12 strain D22 and P. aeruginosa PAO1 are from the University of
Uppsala strain collection (Uppsala, Sweden). The clinical isolates of
E. coli (n = 111), K. pneumoniae (n = 89) and A. baumannii (n = 52) are
from the Innovative Medicines Initiative (IMI) ENABLE collection,
preserved at the University of Uppsala and comprise strains from
Cardiff (Wales, UK), Copenhagen (Denmark), Uppsala (Sweden) and
Warsaw (Poland). A. baumannii strains EN117, EN118, EN151 and
EN152 are from the IMI  ENABLE collection.
2.3. Antibacterial assays
MIC  determinations employing the broth microdilution method
were according to CLSI protocol M07-A10 [1] and used microtiter
plates, cation-adjusted Mueller–Hinton II broth (Difco 212322), and
an inoculum size of 5 × 105 CFU/ml.
MIC  determinations using the agar dilution method also were
according to CLSI protocol M07-A10 [1]. Mueller–Hinton agar
(Becton Dickinson, Oxford, UK) plates containing increasing con-
centrations (0.125– 64 g/ml in 2-fold increments) of the test
substances were used. The agar plates were inoculated (1 l per
spot, corresponding to approximately 104–105 CFU/spot) using a
multipoint inoculator and were incubated for 16–18 h at 35 ± 2 ◦C.
The synergism with rifampin (Sigma–Aldrich) was studied in
microtiter plates as previously described using the fixed rifampin
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.4. Toxicity to human kidney proximal tubular cell line HK2
The HK-2 cell line (CRL-2190TM; American Type Culture Collec-
ion, Manassas, VA, USA) is an immortalized proximal tubule cell
ine derived from a normal human kidney. The assay was  performed
s described in [16]. Cells were cultured in flasks (150 cm2) in 25 ml
f Keratinocyte Serum Free Medium (Invitrogen, Life Technologies
td., Paisley, UK) supplemented with human recombinant epider-
al  growth factor (5 ng/ml) and bovine pituitary extract (50 ng/ml)
nder standard conditions (37 ◦C in 5% CO2). Cultures were main-
ained at 70% confluence with a maximum of 25 passages. For the
ytotoxicity assay, cells were seeded 1 day prior to treatment into
terile 96-well plates at a density of 7.5 × 103 cells/well. Cytotox-
city of the drugs was assessed over a nine-point concentration
ange, starting at a concentration of 1000 g/ml and performing 1:2
erial dilutions. Each concentration was tested in triplicate. Nega-
ive controls (growth medium only) were added to each plate. The
lates were incubated for 24 h, after which the CellTiter-BlueTM
ell viability assay (Promega, Madison, WI,  USA), which measures
onversion of resazurin, was performed according to the manu-
acturer’s instructions. Dose–response curves were plotted and the
alf maximal inhibitory concentration (IC50) values were computed
sing GraphPad PrismTM software (GraphPad Software Inc., La Jolla,
A, USA).
. Results
We  first constructed four mimics of NAB739, each with a dif-
erent hydroxyl-containing amino acid residue at the position R3,
here NAB739 carries D-Ser (Table 1). Compound NAB807 with D-
hr had considerable activity, albeit weaker than that of NAB739,
gainst the E. coli strains used in the screening (ATCC25922 and
H3080). NAB809 carrying D-homoserine (D-HSer) was the weak-
st out of these three compounds. We  have previously shown [13]
nd we also verify it here that NAB743, with L-Ser at R3, is much
ess active than NAB739, with D-Ser at R3, as a directly antibacte-
ial agent. In line with this, NAB805, with L-Thr at R3, and NAB803,
ith L-HSer at R3, did not possess direct antibacterial activity in
he study conditions used here. However, and quite noteworthy,
AB743 has been shown to be very active as a permeabilizer com-
ound [13], as are many other NAB compounds that lack the direct
ntibacterial activity [12–15]. Accordingly, a D-amino acyl at R3 is
ot a prerequisite for an agent with notable permeabilizing activity.
NAB739 is a nonapeptide and hence lacks the amino acid residue
t R1 whereas polymyxin B and colistin do possess R1 and carry the
ositively-charged Dab at this position. Our next step was  to con-
truct tricationic decapeptide compounds where R1 is Dab but that
re designed to lack one of the three positive charges in the ring por-
ion (R4–R10). According to our previous studies, the Dab residue
t R8 appears to be less important for the antibacterial activity than
he Dab residues at R5 and R9 [13,15]. Hence, we introduced R1 with
ab, replaced Dab in R8 with the neutral residues aminobutyric acid
Abu), Ser or Leu, and preserved the hydroxyl-containing D-amino
cid residue (D-Ser as in NAB739, or D-Thr as in NAB807) at R3. Alto-
ether, seven compounds were synthesized, five with octanoyl and
wo with nonanoyl as the fatty acyl tail. Quite remarkably, all dis-
layed MICs identical to or close to those of NAB739 (Table 1, E. coli
trains as targets). A good representative for this class is NAB815,
hich has octanoyl-Dab-Thr-DThr as the linear part and Abu at R8
f the cyclic part.
To better understand the function of Dab as the terminal aminocid residue, we synthesized NAB816, which is otherwise identical
o NAB815 but carries the dipeptide Dab-DThr as the linear peptide
art, instead of the tripeptide Dab-Thr-DThr in NAB815. NAB816
as much less antibacterial than NAB815 (Table 1).s 91 (2017) 8–12 11
Pentacationic polymyxin compounds with the cationic diamino-
propionic acyl (Dap) at R3 have been reported to have increased
antibacterial activity [7]. The tricationic NAB817 which lacks R1 and
carries Dap at R3 and Abu at R8 displayed activity against E. coli but
it was  weaker than NAB815 or NAB739 (Table 1).
Octapeptins are structurally very close to polymyxins but are
octapeptides. They lack the residues R1–R2 of polymyxins and have
a fatty acid tail that is two  methylene units longer than that of
polymyxins [8,11,12]. Furthermore, they carry Leu at R10 whereas
polymyxins carry Thr. Accordingly, they are more hydrophobic than
polymyxins and might even have a nonspecific action against all
biological membranes [12]. Octapeptin A has been reported to be
much more active than polymyxin B against polymyxin-resistant
E. coli strain SC 9253 but, on the other hand, also against Gram-
positive bacteria and eukaryotes [8]. We  have previously shown
that the lipid A part of the lipopolysaccharide (LPS) of SC 9253
is decorated by phosphorylethanolamine and 4-aminoarabinose,
both masking the anionic phosphate/pyrophosphate groups that
are the target of polymyxins [9]. Now we  constructed NAB824,
which is otherwise identical to NAB739 but carries Leu instead of
Thr at R10 (Table 1). NAB824 was more active than NAB739 against
E. coli SC 9253 (MIC medians 16 g/ml and 64 g/for NAB824
and NAB739, respectively), but its median MIC for polymyxin-
susceptible E. coli strains was  as high as 16–32 g/ml. Therefore,
while NAB824 can be regarded as equally active against polymyxin-
susceptible and polymyxin-resistant strains, NAB739 is clearly
superior against polymyxin-susceptible strains.
All the derivatives in Table 1 displayed MICs higher than
16 g/ml for P. aeruginosa ATCC27853 and S. aureus ATCC25923.
We have also previously shown [13] that the reduction of positive
charges in the polymyxin molecule results in weakened activity
against P. aeruginosa.  The absence of the activity against S. aureus
shows that the mode of action of the derivatives constructed is as
specific as in polymyxin B or colistin.
We have previously shown that NAB739 is significantly less
toxic than polymyxin B to human kidney proximal tubular cell line
HK-2 [16]. Table 1 shows that, besides NAB739, all the new deriva-
tives that were tested were also less toxic than polymyxin B to HK-2
cells. For instance, NAB815 was less toxic by a factor of approx. 20.
However, NAB824, the derivative that displayed the best activity
against the polymyxin-resistant E. coli strain SC 9253 (see above),
was only approx. 3–4-fold less toxic than polymyxin B.
We then compared the MICs of NAB815 with those of NAB739
and polymyxin B using an extended set of bacterial strains (Table 2),
including clinical isolates of E. coli (n = 111), K. pneumoniae (n = 89)
and A. baumannii (n = 52). Based on the MIC90 values, NAB815 was
2-fold less active against E. coli and K. pneumoniae and 2-fold more
active against A. baumannii than NAB739. Both agents were some-
what less active than polymyxin B against these three species.
We have previously shown that NAB739 and rifampin are syn-
ergistic against A. baumannii strains [13,15]. Table 2 shows that an
8-fold decrease in the MIC  of NAB739 and NAB815 for A. baumannii
ATCC19606 was  found in the presence of a sub-inhibitory concen-
tration (0.5 g/ml) of rifampin. The MIC  of rifampin for this strain
in the absence of polymyxin B was 4 g/ml. For four clinical A. bau-
mannii strains tested (EN117, EN118, EN151, EN152), the MIC of
NAB815 and NAB739 decreased by factors of 2–4 and 4–8, respec-
tively, in the presence of rifampin, whereas no decrease was found
when polymyxin B was combined with rifampin.
4. DiscussionThis paper showed that it is possible to design remarkably active
antibacterial polymyxins that carry only two  positive charges in the
ring part (i.e. at the positions R5 and R9) and one positive charge
12 M. Vaara et al. / Peptides 91 (2017) 8–12
Table 2
MICs (g/ml) of NAB815, NAB739, and polymyxin B.
NAB815 NAB739 Polymyxin B
E. coli ATCC 25922 1 0.5 0.25
E.  coli ATCC 25922, tolC efflux deficient construct 1 0.5 0.25
E.  coli D22 OM permeability mutant 0.5 1 0.25
E.  coli, clinical isolates (n = 111), MIC90 4 2 1
K.  pneumoniae ATCC 13883 2 2 0.5
K.  pneumoniae, clinical isolates (n = 89), MIC90 8 4 1
A.  baumannii ATCC 19606 4 4 0.5
A.  baumannii ATCC 19606 in the presence of rifampin (0.5 g/ml)a 0.5 [4] 1 [8] 0.5 [1]
A.  baumannii,  clinical isolates (n = 52), MIC90 4 8 1
P.  aeruginosa PAO1 64 16 2

















































peptide PMBN sensitizes E. coli strains to serum bactericidal action, J.Enterococcus faecalis ATCC 29212 
a Determined by broth microdilution. The MIC  of the peptides in the absence of r
n the linear part (at the position R1). Out of the several derivatives
onstructed, NAB815 was studied in more detail.
We have shown elsewhere that in cynomolgus monkeys a very
ignificant portion of the dose of NAB815 and NAB739 is excreted
nto urine within 8 h after an intravenous infusion (0–8 h recovery)
17]. After the infusion of 8 mg/kg of NAB815, the 0–8 h recovery
as 38%, 55%, and 88% of the dose (percentages given for each ani-
al). The corresponding recovery rates for NAB739 were 20%, 91%,
nd 92% and those for polymyxin B 1%, 2%, and 2% [17]. The result-
ng concentrations of NAB815 and NAB739 in the urine were very
igh. After the infusion of NAB815 at 8 mg/kg, concentrations as
igh as 175, 225, and 260 g/ml were found either in the 0–4 or
–8 h sample (concentrations given for each animal). The corre-
ponding concentrations for NAB739 were 80, 140, and 155 g/ml
nd those for polymyxin B 7, 9, and 15 g/ml [17]. The high concen-
rations in the urine explain why NAB815 was more effective than
olymyxin B in the therapy of E. coli murine urinary infection [17].
urthermore, both NAB815 and NAB739 are better tolerated than
olymyxin B in cynomolgus monkeys [17]. Accordingly, the newly
esigned NAB815 as well as the previously described NAB739 both
ave significant advantages over polymyxin B, thus making them
otentially more useful than the old polymyxins in the therapy of
nfections caused by multiresistant Gram-negative bacteria. Fur-
her studies will reveal their role in clinical medicine.
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